- Home
- PCLA vs STRO Comparison
PCLA vs STRO Comparison
Compare PCLA & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCLA
- STRO
- Stock Information
- Founded
- PCLA 2008
- STRO 2003
- Country
- PCLA Japan
- STRO United States
- Employees
- PCLA N/A
- STRO N/A
- Industry
- PCLA Building Products
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PCLA Consumer Discretionary
- STRO Health Care
- Exchange
- PCLA Nasdaq
- STRO Nasdaq
- Market Cap
- PCLA 71.3M
- STRO 77.7M
- IPO Year
- PCLA 2025
- STRO 2018
- Fundamental
- Price
- PCLA $3.25
- STRO $0.76
- Analyst Decision
- PCLA
- STRO Hold
- Analyst Count
- PCLA 0
- STRO 7
- Target Price
- PCLA N/A
- STRO $3.97
- AVG Volume (30 Days)
- PCLA 2.4M
- STRO 1.2M
- Earning Date
- PCLA 01-01-0001
- STRO 08-12-2025
- Dividend Yield
- PCLA N/A
- STRO N/A
- EPS Growth
- PCLA N/A
- STRO N/A
- EPS
- PCLA N/A
- STRO N/A
- Revenue
- PCLA $5,475,228.00
- STRO $66,434,000.00
- Revenue This Year
- PCLA N/A
- STRO N/A
- Revenue Next Year
- PCLA N/A
- STRO N/A
- P/E Ratio
- PCLA N/A
- STRO N/A
- Revenue Growth
- PCLA 40.19
- STRO N/A
- 52 Week Low
- PCLA $0.37
- STRO $0.52
- 52 Week High
- PCLA $9.80
- STRO $5.17
- Technical
- Relative Strength Index (RSI)
- PCLA N/A
- STRO 49.28
- Support Level
- PCLA N/A
- STRO $0.73
- Resistance Level
- PCLA N/A
- STRO $0.83
- Average True Range (ATR)
- PCLA 0.00
- STRO 0.06
- MACD
- PCLA 0.00
- STRO 0.01
- Stochastic Oscillator
- PCLA 0.00
- STRO 61.90
About PCLA PicoCELA Inc. American Depositary Shares
PicoCELA Inc specializes in manufacturing, installing, and servicing enterprise wireless mesh solutions. The company generates revenue from two main sources: product equipment sales, and Software as a Service (SaaS) and maintenance services. The company develops the PCWL series of mesh Wi-Fi access points, which utilize its proprietary PicoCELA Backhaul Engine (PBE) technology to enable wireless communication. The company outsources manufacturing and sells these devices directly to customers through distributors. Additionally, the company offers a cloud portal service in a SaaS model, allowing users to monitor connectivity and traffic at their access points. This platform also supports the installation of proprietary edge-computing software into the devices.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.